Albumin plus blood thinner for severe cirrhosis after hospital recovery
Treatments studied
Part of Digestive system clinical trials.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 80.
- Have decompensated cirrhosis and were admitted to the hospital for a serious liver-related problem (like fluid buildup, confusion, GI bleeding, infection, or a mix).
- Have a CLIF-C AD score of 45 or higher at admission or during your hospital stay.
- Be recovering from the acute problem and expected to be discharged within the next 72 hours.
- Be able to start and follow the study right after this hospital episode, including giving written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.
This trial tests if the blood thinner apixaban can prevent liver cirrhosis from getting worse in people with alcohol-related liver disease. It may help reduce the risk of serious complications like fluid buildup or bleeding.
This trial tests whether a lower dose of albumin works as well as the standard dose for people with cirrhosis and a type of infection called spontaneous bacterial peritonitis (SBP). It aims to see if the low dose can protect kidney function while reducing side effects and costs.
This Phase 4 study looks at how clotting measurements relate to bleeding risk in people with liver cirrhosis who need a planned liver procedure. The study may help doctors understand what coagulation results mean when doing these procedures safely.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.